Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 16,906 Shares

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 16,906 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $24.20, for a total transaction of $409,125.20. Following the completion of the transaction, the director owned 108,504 shares of the company’s stock, valued at $2,625,796.80. The trade was a 13.48% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total transaction of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The shares were sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Price Performance

NASDAQ IMNM opened at $24.39 on Wednesday. The business has a fifty day moving average price of $20.99 and a two-hundred day moving average price of $21.83. The stock has a market capitalization of $2.76 billion, a PE ratio of -10.25 and a beta of 2.07. Immunome, Inc. has a fifty-two week low of $7.96 and a fifty-two week high of $27.65.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, sell-side analysts expect that Immunome, Inc. will post -2.06 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in IMNM. Bank of America Corp DE grew its holdings in Immunome by 285.6% during the 1st quarter. Bank of America Corp DE now owns 781,607 shares of the company’s stock worth $17,094,000 after acquiring an additional 578,890 shares during the last quarter. Edgestream Partners L.P. bought a new position in shares of Immunome during the first quarter valued at $1,310,000. California State Teachers Retirement System lifted its holdings in shares of Immunome by 66.3% during the first quarter. California State Teachers Retirement System now owns 111,444 shares of the company’s stock worth $2,437,000 after purchasing an additional 44,432 shares during the period. Quantinno Capital Management LP acquired a new position in shares of Immunome during the first quarter worth $222,000. Finally, Aristotle Atlantic Partners LLC bought a new stake in shares of Immunome in the first quarter worth $2,734,000. Institutional investors own 44.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on IMNM shares. Wall Street Zen cut shares of Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Leerink Partners cut their target price on shares of Immunome from $37.00 to $33.00 and set an “outperform” rating on the stock in a research report on Friday, May 15th. Truist Financial boosted their target price on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research note on Thursday, May 28th. Barclays assumed coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price on the stock. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunome in a research note on Tuesday, April 21st. Twelve research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $33.17.

About Immunome

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.